JP Morgan Chase
BIAF icon

JP Morgan Chase’s bioAffinity Technologies BIAF Stock Holding History

JP Morgan Chase’s Portfolio BIAF Stock Details BIAF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1
Closed -$5 – 7085
2025
Q1 		$5 Hold
1
– – ﹤0.01% 7223
2024
Q4 		$20 Hold
1
– – ﹤0.01% 7268
2024
Q3 		$44 Hold
1
– – ﹤0.01% 7134
2024
Q2 		$39 Buy
+1
New +$69 ﹤0.01% 7067
2024
Q1 		– Hold
0
– – – 7136
2023
Q4 		– Hold
0
– – – 7399
2023
Q3 		– Hold
0
– – – 7305

Other funds holding BIAF

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

JP Morgan Chase's BIAF Position: Q2 2025 in Review

JP Morgan Chase sold out of bioAffinity Technologies (BIAF) in Q2 2025, closing a stake of 1 share — an estimated $5 sold.

JP Morgan Chase first reported a position in BIAF in Q2 2024 and held it in 4 quarters. The position peaked at $44 in Q3 2024. 17 funds tracked by Wall St. Rank hold BIAF as of Q2 2025.

  • JP Morgan Chase reported no remaining bioAffinity Technologies position as of Q2 2025 after selling out during the quarter.
  • JP Morgan Chase sold 1 bioAffinity Technologies share in Q2 2025, an estimated $5.
  • JP Morgan Chase first reported a position in bioAffinity Technologies in Q2 2024 and held it in 4 quarters.
  • JP Morgan Chase's bioAffinity Technologies position peaked at $44 in Q3 2024.
  • 17 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.